Literature DB >> 30363515

Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.

Srivadee Oravivattanakul1,2, Lucas Benchaya1, Guiyun Wu3, Anwar Ahmed1, Ilia Itin1, Scott Cooper1, Michal Gostkowski1, Joseph Rudolph1, Kristin Appleby1, Patrick Sweeney1, Hubert H Fernandez1.   

Abstract

BACKGROUND: The aim of this work was to describe utilization patterns of dopamine transporter (DaT) scan and its influence on patient management at a single movement disorders center. DaT scan helps differentiate between neurodegenerative from non-neurodegenerative parkinsonism and essential tremor (ET). It has been recently approved in the United States in 2011.
METHODS: We conducted a retrospective review of all patients, observed by movement disorders neurologists, who received a DaT scan. Demographic data, medication use, and prescan diagnosis were collected.
RESULTS: A total of 216 DaT scans were performed at our center from 1 June 2011 to 31 October 2012. A total of 175 scans were included for analysis. Rates of DaT scan utilization varied from 5 to 33 per 100 new patients observed. When our specialists suspected neurodegenerative parkinsonism before the scan (N = 70), the scan was abnormal in 57%. When non-neurodegenerative parkinsonism was prescan diagnosis (N = 46), the scan was normal in 65%. When essential/dystonic tremor was suspected (N = 14), the scan was normal in 79%. When psychogenic disorder was the prescan diagnosis (N = 15), the scan was normal in only 47%. Only 4% of patients with abnormal scan remained off anti-PD medications, whereas 24% of patients with negative scan were still on anti-PD medications.
CONCLUSIONS: DaT scan utilization among specialists varied greatly. Scan results correlated most when prescan diagnosis was ET than when working diagnosis was neurodegenerative parkinsonism or other non-neurodegenerative parkinsonism. Scan result was least consistent when prescan diagnosis was psychogenic disorder. Finally, DaT scans influenced medical treatment more when it was abnormal, compared to when it was normal.

Entities:  

Keywords:  dopamine transporter single‐photon emission computed tomography (SPECT) scan; neuroimaging; parkinsonism

Year:  2015        PMID: 30363515      PMCID: PMC6178596          DOI: 10.1002/mdc3.12261

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  7 in total

1.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123 I]-FP-CIT SPECT imaging: The [123 I]-FP-CIT study group.

Authors:  Hani T S Benamer; Jim Patterson; Donald G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H I M Horstink; H J W A Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

Review 2.  [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.

Authors:  Robert A Hauser; Donald G Grosset
Journal:  J Neuroimaging       Date:  2011-03-16       Impact factor: 2.486

3.  Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study.

Authors:  Andreas R Kupsch; Nin Bajaj; Frederick Weiland; Antonio Tartaglione; Susanne Klutmann; Melanie Buitendyk; Paul Sherwin; Ann Tate; Igor D Grachev
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-04-06       Impact factor: 10.154

Review 4.  The role of DAT-SPECT in movement disorders.

Authors:  G Kägi; K P Bhatia; E Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-01       Impact factor: 10.154

5.  Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes.

Authors:  Ana M Catafau; Eduardo Tolosa
Journal:  Mov Disord       Date:  2004-10       Impact factor: 10.338

6.  Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Authors:  Vicky L Marshall; Cornelia B Reininger; Moritz Marquardt; Jim Patterson; Donald M Hadley; Wolfgang H Oertel; Hani T S Benamer; Paul Kemp; David Burn; Eduardo Tolosa; Jamie Kulisevsky; Luis Cunha; Durval Costa; Jan Booij; Klaus Tatsch; K Ray Chaudhuri; Gudrun Ulm; Oliver Pogarell; Helmut Höffken; Anja Gerstner; Donald G Grosset
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

Review 7.  Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.

Authors:  Werner Poewe; Christoph Scherfler
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

  7 in total
  7 in total

1.  Comment on: Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.

Authors:  Shakya Bhattacharjee; Vijaya Shankar; Mohammed Elkider
Journal:  Mov Disord Clin Pract       Date:  2016-05-09

2.  Reply to Comment on: Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center.

Authors:  Srivadee Oravivattanakul; Lucas Benchaya; Anwar Ahmed; Ilia Itin; Scott Cooper; Michal Gostkowski; Joseph Rudolph; Kristin Appleby; Patrick Sweeney; Hubert H Fernandez; Guiyun Wu
Journal:  Mov Disord Clin Pract       Date:  2016-07-28

Review 3.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

4.  Analysis of the Effect of Dopamine Transporter Scan on the Diagnosis and Management in a Tertiary Neurology Center.

Authors:  Shakya Bhattacharjee; Vijayashankar Paramanandam; Atrayee Bhattacharya
Journal:  Neurohospitalist       Date:  2019-02-14

Review 5.  Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis.

Authors:  Danny Bega; Phillip H Kuo; Anastasia Chalkidou; Mariusz T Grzeda; Thomas Macmillan; Christine Brand; Zulfiqar H Sheikh; Angelo Antonini
Journal:  NPJ Parkinsons Dis       Date:  2021-05-24

6.  Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease.

Authors:  Jonathan R Isaacson; Salima Brillman; Nisha Chhabria; Stuart H Isaacson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

7.  Correlation between 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in patients with Parkinson's disease: a pilot study.

Authors:  Julieta E Arena; Leandro Urrutia; Germán Falasco; Magdalena Ponce de Leon; Silvia Vazquez; Malco Rossi; Marcelo Merello
Journal:  Radiol Bras       Date:  2021 Jul-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.